Quin E Denfeld1, Christopher S Lee, William R Woodward, Shirin O Hiatt, James O Mudd, Beth A Habecker. 1. Quin E. Denfeld, PhD, RN Knight Cardiovascular Institute and Department of Physiology & Pharmacology, Oregon Health & Science University, Portland. Christopher S. Lee, PhD, RN, FAAN, FAHA, FHFSA William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts. William R. Woodward, PhD Department of Physiology & Pharmacology and Department of Neurology, Oregon Health & Science University, Portland. Shirin O. Hiatt, MS, RN, MPH School of Nursing, Oregon Health & Science University, Portland. James O. Mudd, MD Knight Cardiovascular Institute, Oregon Health & Science University, Portland. Beth A. Habecker, PhD Knight Cardiovascular Institute and Department of Physiology & Pharmacology, Oregon Health & Science University, Portland.
Abstract
BACKGROUND: Clinical response to left ventricular assist devices (LVADs), as measured by health-related quality of life, varies among patients after implantation; however, it is unknown which pathophysiological mechanisms underlie differences in clinical response by health-related quality of life. OBJECTIVE: The purpose of this study was to compare changes in sympathetic markers (β-adrenergic receptor kinase-1 [βARK1], norepinephrine [NE], and 3,4-dihydroxyphenylglycol [DHPG]) between health-related quality of life clinical responders and nonresponders from pre- to post-LVAD implantation. METHODS: We performed a secondary analysis on a subset of data from a cohort study of patients from pre- to 1, 3, and 6 months after LVAD implantation. Clinical response was defined as an increase of 5 points or higher on the Kansas City Cardiomyopathy Questionnaire Clinical Summary score from pre- to 6 months post-LVAD implantation. We measured plasma βARK1 level with an enzyme-linked immunosorbent assay and plasma NE and DHPG levels with high-performance liquid chromatography with electrochemical detection. Latent growth curve modeling was used to compare the trajectories of markers between groups. RESULTS: The mean (SD) age of the sample (n = 39) was 52.9 (13.2) years, and most were male (74.4%) and received LVADs as bridge to transplantation (69.2%). Preimplantation plasma βARK1 levels were significantly higher in clinical responders (n = 19) than in nonresponders (n = 20) (P = .001), but change was similar after LVAD (P = .235). Preimplantation plasma DHPG levels were significantly lower in clinical responders than in nonresponders (P = .002), but the change was similar after LVAD (P = .881). There were no significant differences in plasma NE levels. CONCLUSIONS: Preimplantation βARK1 and DHPG levels are differentiating factors between health-related quality of life clinical responders and nonresponders to LVAD, potentially signaling differing levels of sympathetic stimulation underlying clinical response.
BACKGROUND: Clinical response to left ventricular assist devices (LVADs), as measured by health-related quality of life, varies among patients after implantation; however, it is unknown which pathophysiological mechanisms underlie differences in clinical response by health-related quality of life. OBJECTIVE: The purpose of this study was to compare changes in sympathetic markers (β-adrenergic receptor kinase-1 [βARK1], norepinephrine [NE], and 3,4-dihydroxyphenylglycol [DHPG]) between health-related quality of life clinical responders and nonresponders from pre- to post-LVAD implantation. METHODS: We performed a secondary analysis on a subset of data from a cohort study of patients from pre- to 1, 3, and 6 months after LVAD implantation. Clinical response was defined as an increase of 5 points or higher on the Kansas City Cardiomyopathy Questionnaire Clinical Summary score from pre- to 6 months post-LVAD implantation. We measured plasma βARK1 level with an enzyme-linked immunosorbent assay and plasma NE and DHPG levels with high-performance liquid chromatography with electrochemical detection. Latent growth curve modeling was used to compare the trajectories of markers between groups. RESULTS: The mean (SD) age of the sample (n = 39) was 52.9 (13.2) years, and most were male (74.4%) and received LVADs as bridge to transplantation (69.2%). Preimplantation plasma βARK1 levels were significantly higher in clinical responders (n = 19) than in nonresponders (n = 20) (P = .001), but change was similar after LVAD (P = .235). Preimplantation plasma DHPG levels were significantly lower in clinical responders than in nonresponders (P = .002), but the change was similar after LVAD (P = .881). There were no significant differences in plasma NE levels. CONCLUSIONS: Preimplantation βARK1 and DHPG levels are differentiating factors between health-related quality of life clinical responders and nonresponders to LVAD, potentially signaling differing levels of sympathetic stimulation underlying clinical response.
Authors: John Spertus; Eric Peterson; Mark W Conard; Paul A Heidenreich; Harlan M Krumholz; Philip Jones; Peter A McCullough; Ileana Pina; Joseph Tooley; William S Weintraub; John S Rumsfeld Journal: Am Heart J Date: 2005-10 Impact factor: 4.749
Authors: Jonathan A Hata; Matthew L Williams; Jacob N Schroder; Brian Lima; Janelle R Keys; Burns C Blaxall; Jason A Petrofski; Andre Jakoi; Carmelo A Milano; Walter J Koch Journal: J Card Fail Date: 2006-06 Impact factor: 5.712
Authors: Maaike G J Gademan; Cees A Swenne; Harriette F Verwey; Arnoud van der Laarse; Arie C Maan; Hedde van de Vooren; Johannes van Pelt; Henk J van Exel; Caroline M H B Lucas; Ger V J Cleuren; Soeresh Somer; Martin J Schalij; Ernst E van der Wall Journal: J Card Fail Date: 2007-05 Impact factor: 5.712
Authors: Quin E Denfeld; Julie T Bidwell; Jill M Gelow; James O Mudd; Christopher V Chien; Shirin O Hiatt; Christopher S Lee Journal: Heart Lung Date: 2019-11-18 Impact factor: 2.210